You Position: Home > Paper
聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎的临床研究
( views:125, downloads:8 )
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1674-2397.2008.05.012
- Key Word:
- No keyword available
Abstract： @@ 迄今,慢性乙型肝炎(CHB)尚缺乏特效治疗.目前认为,抗病毒治疗是关键.笔者自2004年1月-2006年12月对HBeAg阳性的CHB患者采用聚乙二醇干扰素α-2a(PegIFNα-2a,上海罗氏制药有限公司生产)治疗,取得了较好的疗效,现报道如下.
- [1]陈栋,姚光弼,陈文.聚乙二醇干扰素α-2a与拉米夫定治疗HBeAg阳性慢性乙型肝炎的经济学评价[J].2007,(8).
- [2]Keam SJ,Cvetkovic RS.Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection.[J].2008,68(9).
- [3]Marcellin P,Lau GK,Bonino F,etc.Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.[J].2004,351(12).
- [4]M, Rumi,R, Romeo,F, De Filippi,etc.A multicentre randomized clinical trial of recombinant alpha-2a interferon therapy in patients with chronic hepatitis B.[J].1993,25(3).
- [5]H. C. Thomas,A. S. F. Lok,V. Carreño,etc.Comparative study of three doses of interferon-α2a in chronic active hepatitis B[J].1994,1(2).
- [6]Lee SD,Tanwandee T,Cooksley WG,etc.Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.[J].2003,10(4).